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Abstract
Introduction: Patients with Alzheimer’s disease (AD) are currently treated with cholinesterase inhibitors, such as
galantamine, without actual knowledge of its concentration in plasma. Our objective was to analyse potential
relationships between galantamine concentration, galantamine dose, socio-demographic characteristics, body
weight, body mass index (BMI), and treatment response.
Methods: Eighty-four patients with AD recruited from the Memory Clinic, Malmö, Sweden, and treated with
galantamine were included in the study. Efficacy measures, including cognition (Mini-Mental State Examination
(MMSE), Alzheimer’s Disease Assessment Scale - cognitive subscale (ADAS-cog)) and instrumental activities of daily
living (IADL), were evaluated at baseline, 2 months after treatment initiation (MMSE only) and semi-annually over 3
years. At these assessments, blood samples were obtained for the analysis of the galantamine concentration, and
body weight, BMI, drug dose and time from drug intake were recorded.
Results: All patients had a measurable concentration of galantamine at all assessments. The mean plasma
concentration of the drug exhibited a positive linear association with dose (r = 0.513, P < 0.001). The dose did not
differ between sexes. Negative linear associations between the galantamine plasma concentration and BMI (r =
-0.454, P = 0.001) or body weight (r = -0.310, P = 0.034) were found exclusively in the male group. When mixed-
effects models were used, the dose of galantamine (P < 0.001), time from drug intake (P < 0.001), and BMI (P =
0.021) or weight (P = 0.002) were factors that predicted the concentration, whereas sex, age, and cognitive and
functional changes were not.
Conclusions: High compliance to galantamine treatment was found among all patients in this naturalistic AD
study. The impact of BMI or body weight on the plasma concentration of galantamine was important only among
males. No relationship was observed between concentration and short-term treatment response or progression
rate in terms of cognitive and functional abilities.
Introduction
Currently, acetylcholinesterase inhibitors (ChEIs) are used
as a symptomatic treatment to counteract the progressive
and devastating symptoms of Alzheimer’s disease (AD).
ChEIs prevent the degradation of acetylcholine (ACh) by
inhibiting the enzyme acetylcholinesterase (AChE), result-
ing in increased levels of ACh in the synaptic cleft avail-
able for receptor absorption. This enhances cholinergic
transmission and improves the communication between
neurons [1]. Galantamine is a specific, competitive and
reversible ChEI that was approved in Sweden in 2000.
Moreover, it is an allosteric modulator at nicotinic choli-
nergic receptor sites that potentiates cholinergic nicotinic
neurotransmission, which provides this ChEI agent with a
dual mechanism of action [2]. The half-life of galantamine
is 7 to 8 hours. Therefore, to simplify dosing and enhance
compliance, a once-daily prolonged-release capsule of
galantamine was developed [3].
Galantamine, as well as the other two ChEIs available
currently (donepezil and rivastigmine), yields modest
improvements in cognition, global performance and
activities of daily living (ADL) compared with placebo
treatment in subjects with varying degrees of AD severity
[4]. However, a large heterogeneity in the response to,
and long-term outcome of, ChEI treatment has been
observed among individual patients. A meta-analysis
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demonstrated that larger ChEI doses are related to a bet-
ter cognitive outcome [5] and an extension study sug-
gested that effective dosages and sustained use might
postpone the time to nursing home placement [6].
Furthermore, a more positive response to ChEI therapy
has been reported among men compared with women
[7,8].
Patients with AD are currently treated with ChEIs
without actual knowledge of their concentration in
plasma. Few studies have investigated whether drug con-
centration is a factor that influences the heterogeneity of
the response to ChEI treatment. A relationship has been
observed between the levels of AChE in the brain and
in the cerebrospinal fluid (CSF) after treatment with
galantamine. In addition, positive correlations have been
found between AChE inhibition and the results of cog-
nitive tests, mainly of those measuring attention [9].
Another AD study reported a dose-dependent increase
in CSF AChE levels after ChEI therapy, and the increase
was more prominent in patients showing a cognitive
response according to the Mini-Mental State Examina-
tion (MMSE) test [10]. Those studies had the limitation
of including small sample sizes and shorter follow-up
intervals, and the fact that most patients originated from
randomised trials.
It remains to be investigated whether a higher dose of
galantamine or a higher drug plasma concentration cor-
relates to a better cognitive and functional outcome in
naturalistic patients with AD. Furthermore, other ques-
tions, such as whether drug plasma concentration differs
between sexes or among patients with varying body
mass index (BMI), need to be answered. Increased
knowledge of these factors is clinically important and
might lead to a better management of patients and
enhanced drug efficacy. To address these questions, we
investigated the plasma concentration levels of galanta-
mine in a cohort of patients with AD in a routine clini-
cal setting. The aims of this study were to investigate
the associations between the plasma concentration of
galantamine and sex, BMI, body weight, dose of galanta-




The patients were recruited prospectively from the
Memory Clinic of the Skåne University Hospital in
Malmö and enrolled in the Swedish Alzheimer Treat-
ment Study (SATS). The study was undertaken to inves-
tigate the long-term effectiveness of ChEI treatment in
naturalistic AD patients on various aspects of the dis-
ease (for example, cognitive, global and functional
aspects). The SATS is a 3-year, open-label, non-rando-
mised, multicentre study performed in a routine clinical
setting. Most patients were in the mild-to-moderate
stage of AD. The work-up at baseline included medical
history, informant-based information, physical and neu-
rological examination, extended cognitive testing,
laboratory tests and computed tomography (CT) or
magnetic resonance imaging (MRI) of the brain. Patients
fulfilling the clinical criteria of dementia, as defined by
the Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV) [11], and those of probable
or possible AD, according to the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) [12], were included in
this study. Furthermore, the inclusion criteria were: AD
patient older than 40 years, living at home at the time
of diagnosis, having a responsible caregiver, and assessa-
ble with MMSE at baseline. Patients not fulfilling the
diagnostic criteria for AD, those already undergoing
active treatment with any ChEI drug, or individuals with
contraindications for ChEI therapy were excluded from
the study.
From January 2005 and for 2 years onwards, during
their visits to the Memory Clinic the galantamine-trea-
ted SATS patients were consecutively asked to give
blood samples for inclusion in this study. Eighty-four
patients with AD provided repeat blood samples after
treatment was initiated. The baseline characteristics of
patients were recorded, including sex, apolipoprotein E
(APOE) genotype, clinician’s estimate of age at onset
and duration of the disease, age at start of galantamine
therapy, years of education and BMI.
Outcome measures
The patients were assessed using cognitive, global and
functional rating scales at the start of galantamine treat-
ment, at 2 months (MMSE only) after the initiation of
treatment and every 6 months over the course of 3
years. Trained dementia nurses obtained the ADL eva-
luation from an interview with the caregiver. In addi-
tion, BMI was calculated at every assessment using the
formula body weight in kilograms/height in meters
squared. The height of patients was measured once,
whereas body weight in kilograms was measured at
every assessment after the start of ChEI therapy. The
reasons for dropping out of the study, such as adverse
events, were recorded.
Cognitive ability was evaluated using the MMSE [13],
with scores ranging from 0 to 30 (a higher score indicat-
ing less impaired cognition), and the Alzheimer’s Dis-
ease Assessment Scale-cognitive subscale (ADAS-cog)
[14], with a total score ranging from 0 to 70 (a higher
score indicating more impaired cognition). Functional
ability was measured using the Instrumental Activities
of Daily Living (IADL) scale [15]. The latter consists of
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eight different items: telephone usage, shopping, food
preparation, housekeeping, laundry, mode of transporta-
tion, responsibility for own medications and managing
finances. Each item was scored from 1 (no impairment)
to 3 to 5 (severe impairment), which resulted in a total
score ranging from 8 to 31 points.
The rates of cognitive and functional change were calcu-
lated using three methods: 1) the change in score from the
start of galantamine treatment (baseline) to the assessment
with plasma extraction, divided by the number of months
between these assessments; 2) the change in score from
the previous assessment to the assessment with plasma
extraction, divided by the number of months (usually 6)
between these assessments; and 3) divided into two groups
based on the patients’ cognitive or functional rates of
change per month during the study, that is, fast and slow
decliners (cut-off median), using MMSE, ADAS-cog or
IADL scores. To facilitate the comparison of MMSE,
ADAS-cog and IADL scores, changes in score were con-
verted to positive values, which were indicative of
improvement, and negative values, which were indicative
of decline.
Galantamine treatment
After inclusion and baseline assessments, patients
received galantamine treatment according to the
approved product labelling, as in routine clinical practice.
Patients were started on a dose of 8 mg per day, which
was increased to 16 mg per day after 4 weeks of treat-
ment, aiming at a further dose increase to 24 mg per day.
In some cases, the dose was reduced because of side
effects. All decisions regarding dosage were left to indivi-
dual clinicians, as in routine clinical practice, and all
dosage adjustments were recorded throughout the study.
The patients paid for their medication in accordance
with the standards of the Swedish healthcare system.
All patients and/or caregivers provided informed con-
sent to participate in the study, which was conducted
according to the provisions of the Helsinki Declaration
and was approved by the Ethics Committee of Lund
University, Sweden.
Biochemical analysis
The plasma concentration of galantamine was deter-
mined using reversed-phase high-performance liquid
chromatography with fluorescence detection [16]. The
limit of detection of this method is 0.015 μmol/L and
the coefficient of variation (CV) is 11.4% at a plasma
level of 0.1 μmol/L and 4.3% at 2.0 μmol/L.
Statistical analyses
The IBM SPSS statistics software version 19.0 (SPSS
Inc., Chicago, IL, USA) was used to perform statistical
analyses. The level of significance was defined as P <
0.05 if not otherwise specified. One-way analysis of var-
iance (ANOVA) with the Bonferroni correction was
used to compare the difference between the mean galan-
tamine plasma concentrations according to galantamine
dose. Independent samples t-tests were computed for
the analysis of concentration or mean dose between
sexes or APOE genotypes (two groups, presence or
absence of ε4 allele). Pearson’s correlation coefficient
was calculated to investigate the presence of any linear
associations between plasma concentration and the fol-
lowing variables: age at baseline, duration of AD, BMI,
body weight, and cognitive and functional ability. Spear-
man’s non-parametric correlation coefficient was used
to analyse the ordinal variable drug dose.
Mixed-effects models with the galantamine plasma
concentration as the dependent variable and study sub-
ject as a hierarchical variable (that is, to allow within-
subject correlations) were used to study the multivariate
impact on the abovementioned independent variables
and the time from drug intake to plasma extraction as
the fixed-effect terms. The random term in the models
was an intercept with a variance components covariance
matrix. Because of the strong linear correlation between
the MMSE and ADAS-cog scores, these variables were
entered into the models separately. Similarly, BMI and
body weight were also entered individually. In a second
mixed-effects model, the rates of change per month in
MMSE (or ADAS-cog) and IADL scores were included,




The baseline characteristics and cognitive and functional
outcomes for the entire cohort (n = 84) and for the 31
patients (37%) who were assessed after 3 years of galan-
tamine treatment are described in Table 1.
Galantamine plasma concentration
All patients had measurable levels of galantamine at all
time points. The mean number ± SD (range) of blood
samples per patient was 2.1 ± 1.3 (1 to 6). The number
of samples obtained after each assessment was: 47 at 2
months, 41 at 6 months, 33 at 12 months, 18 at 18
months, 18 at 24 months, 12 at 30 months and 11 at 36
months of ChEI treatment; thus, 180 samples were
acquired in total. The mean galantamine plasma con-
centration exhibited a strong positive linear association
with drug dose (rs = 0.513, P < 0.001).
The mean ± SD dose of galantamine administered dur-
ing the study was 14.0 ± 3.1 mg per day. Patients who
received different daily doses of galantamine, namely 8 mg
(n = 36), 16 mg (n = 108) and 24 mg (n = 34) (data were
missing for two doses), differed significantly in mean ± SD
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plasma concentration (0.163 ± 0.073, 0.261 ± 0.105 and
0.368 ± 0.145 μmol/L, respectively; P < 0.001). Figure 1
suggests the presence of a stronger negative linear associa-
tion between plasma concentration and time from drug
intake to plasma extraction among the individuals treated
with 24 mg (r = -0.637, P < 0.001) and 16 mg (r = -0.414,
P < 0.001) compared with 8 mg of galantamine (r =
-0.277, P = 0.113).
Age at baseline, duration of AD and cognitive and
functional abilities at the start of treatment did not cor-
relate with the plasma concentration or mean dose of
galantamine. Four individuals withdrew from the study
because of adverse events. The galantamine plasma con-
centrations of these individuals did not differ from those
of the other patients.
Sex
Male patients had a significantly lower mean galanta-
mine plasma concentration compared with female
patients (0.218 ± 0.103 vs 0.277 ± 0.129 μmol/L, P =
0.005). No sex differences in the mean dose of galanta-
mine were observed. No differences in the presence of
the APOE ε4 allele, age at onset or at baseline, duration
of AD, education in years and cognitive or functional
abilities at baseline were detected between sexes.
BMI and body weight
There were no linear, quadratic, or cubic relationships
between the galantamine plasma concentration and BMI
in the entire cohort. Investigation of the impact of sex
revealed the presence of a negative linear association (r
= -0.454, P = 0.001) between the galantamine plasma
concentration and BMI exclusively in the male group.
The addition of higher-degree polynomials slightly
strengthened the explanation of the variance (linear R2
= 0.206, P = 0.001; quadratic and cubic R2 = 0.239, P =
0.002). The results of the quadratic model are illustrated
(Figure 2a).
There was a negative linear association between the
galantamine plasma concentration and body weight in
the total cohort (r = -0.268, P < 0.001). As for the vari-
able BMI, only the male group exhibited a significant
linear relationship (r = -0.310, P = 0.034) (Figure 2b).
The inclusion of quadratic and cubic terms marginally
increased the degree to which the variance was
explained. Therefore, the results of the linear model are
presented.
There was no significant correlation between the
change in the galantamine plasma concentration and the
change in BMI or body weight in the entire cohort or
when the sexes were analysed separately. However, the
body weights of only 10 patients (all women) changed
by more than ± 2 kilograms during the study. No linear
association between the change in the plasma concen-
tration and the change in BMI or body weight was
found when only these individuals were analysed.
Cognitive and functional outcomes
The changes in MMSE, ADAS-cog or IADL scores from
the start of ChEI therapy to the 2-month (MMSE only),
6-month or 12-month assessment, respectively, did not
correlate with galantamine plasma concentration. No
significant linear relationships were found between
plasma concentration and cognitive or functional rate of
change per month using any of the three calculation
methods. Patients receiving different doses of galanta-
mine (8, 16 or 24 mg daily) did not differ in cognitive
or functional changes/month.
Although there were no significant associations
between the rates of change and the plasma concentra-
tion, the mean differences (with the 95% CIs) in cogni-
tion and function from the start of galantamine
treatment to the 2-month (MMSE only) and 6-month
assessments are presented for each quartile of the
plasma concentration (Table 2).
Multivariate analyses
Mixed-effects models using the galantamine plasma con-
centration as the dependent variable revealed that the
drug dose (P < 0.001), time from drug intake (P <
0.001), and BMI (P = 0.021) or body weight (P = 0.002)
were significant predictors of the drug concentration.
The independent variables, sex, APOE genotype, age at
baseline, duration of AD, and the MMSE (or ADAS-
cog) and IADL scores at baseline were not significant
predictors of the galantamine plasma concentration in
the models. The cognitive and functional rates of change
per month were also entered as independent predictors
in the mixed-effects models, but these variables showed





Number of patients 84 31
Female sex, n (%) 60 (71%) 21 (68%)
APOE ε4 carrier, n (%) 57 (69%) 21 (68%)
Age at onset, yearsa 73.9 ± 7.1 73.3 ± 8.8
Age at start of treatment, yearsa 76.7 ± 7.0 76.9 ± 8.2
Illness duration, yearsa 3.0 ± 1.8 3.6 ± 2.3
Education, yearsa 10.1 ± 2.9 9.9 ± 2.9
MMSE score at baselinea 22.7 ± 4.0 23.2 ± 3.8
ADAS-cog score (0 to 70) at
baselinea
17.1 ± 8.2 15.2 ± 8.3
IADL score at baselinea 13.4 ± 5.0 14.0 ± 6.0
MMSE score after 3 yearsa (n = 31) 21.7 ± 4.6
ADAS-cog score after 3 yearsa
(n = 29)
20.7 ± 13.2
IADL score after 3 yearsa (n = 24) 22.6 ± 5.8
aMean ± standard deviation. ADAS-cog, Alzheimer’s Disease Assessment Scale-
cognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of
Daily Living scale; MMSE, Mini-Mental State Examination.
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no significant relationship to the plasma concentration
of galantamine.
Discussion
In this study, we found that all patients included had a
measurable concentration of galantamine at all assess-
ment points. The mean galantamine plasma concentra-
tion exhibited a strong positive linear association with
drug dose. Moreover, no sex differences regarding drug
dose were observed. A negative linear association
between the galantamine plasma concentration and BMI
or body weight was found in the male, but not in the
female group. The dose of galantamine, time from drug
intake, and BMI or weight were predictive factors in the
multivariate mixed-effects models in which the plasma
concentration was used as the dependent variable. The
galantamine plasma concentration showed no linear
association with age, the cognitive or functional
responses to ChEI treatment, or the longitudinal AD
progression rate.
Currently, naturalistic patients with AD are treated
with ChEIs without actual knowledge of their plasma or
CSF concentration. Few studies have focused on whether
drug concentration is a factor that affects the heterogene-
ity of the response to ChEI therapy. A small study of
patients with mild AD reported that AChE levels in the
CSF and in the brain are significantly correlated, both
before and after treatment with galantamine [9]. A recent
study reported positive and dose-related correlation
between the plasma concentration of donepezil and
increased AChE activity in the CSF. Treatment with
galantamine also caused an increase in CSF AChE activ-
ity, but the increase was not dose dependent; however,
the sample size was small (n = 15) and galantamine































Figure 1 Galantamine plasma concentration, dose and time from drug intake. Time from drug intake to plasma extraction and
galantamine plasma concentration level. The different galantamine doses are displayed: 8 mg, blue star; 16 mg, green star; 24 mg, red star. The
lines illustrate a stronger negative linear association between galantamine plasma concentration and time from galantamine intake to plasma
extraction among the individuals treated with 24 mg (r = -0.637, P < 0.001) and 16 mg (r = -0.414, P < 0.001) compared with those treated with
8 mg (r = -0.277, P = 0.113).
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plasma concentration was not addressed in that study
[17]. The increase in CSF AChE activity has been sug-
gested as being greater in donepezil-treated compared
with galantamine-treated patients [10,17] and sustained
in rivastigmine-treated patients [18,19]. This was
explained by different mechanisms of action of the sub-
stances used as reversible AChE inhibitors (donepezil,
galantamine), and the substance used as a pseudo-irre-
versible AChE inhibitor (rivastigmine). Although the
three ChEIs display various biochemical mechanisms and
their effect on AChE activity might vary, the observed
long-term treatment effect evaluated using cognitive and
ADL scales does not seem to differ among the drugs
[8,20,21]. Moreover, the plasma concentration of donepe-
zil was 10 times higher in the blood than it was in the
CSF; nevertheless, donepezil exhibited similar dose-
dependent kinetics in that study [22]. In summary, these
reports suggest that it is possible to identify a biochem-
ical effect of ChEIs and to measure this effect in a dose-
related manner.
In the present study, galantamine plasma concentra-
tion, but not AChE inhibition, was measured. Darreh-
Shori et al. [22] suggested that the cognitive changes in
patients with AD should be assessed in relation to AChE
inhibition rather than ChEI dose. However, a meta-analy-
sis showed that higher doses of donepezil and rivastig-
mine were associated with a better cognitive outcome.
This dose effect was not described for galantamine [5].
However, a naturalistic long-term study performed by
our group and including the three ChEIs reported that
higher doses of ChEI were related to a more positive
cognitive outcome, regardless of the type of drug [8]. The
ChEIs might have different mechanisms of action and
effects on AChE. Galantamine is a reversible AChE inhi-
bitor with a competitive mode of action, which means
that the degree of inhibition caused by the drug does not
depend on the absolute concentration of galantamine;
rather, it is more dependent on the association between
the inhibitor and substrate concentration. Galantamine
also potentiates cholinergic nicotinic neurotransmission
by allosterically modulating the nicotinic receptors [2].
These mechanisms might cause the appearance of phar-
macological effects early and at low concentrations; thus,
a higher dose might not influence drug efficacy.
Men exhibited a lower galantamine plasma concentra-
tion compared with women in the present study, but no
sex difference was found regarding drug dose. A nega-
tive linear correlation between the galantamine plasma
concentration and BMI or body weight was found only
in the male group, that is, men with higher BMI or
weight exhibited lower galantamine plasma concentra-
tions. This finding agrees with the results of a large
study performed by Piotrovsky et al. [23], who observed
that galantamine clearance was enhanced in men
because of their greater body weight. In that study, and
in ours when we used multivariate mixed-effects models,
the dissimilarities in galantamine clearance were depen-
dent on body weight but not on sex. However, a better
response to ChEI treatment in men compared with
women was reported previously [7,8].
A linear association between drug plasma concentra-
















































































Figure 2 Galantamine plasma concentration, sex, and body mass index or body weight. a) Body mass index showed a quadratic
relationship with the galantamine plasma concentration exclusively in male patients (R2 = 0.239, P = 0.002). b) Body weight showed a negative
correlation with the galantamine plasma concentration exclusively among male patients (r = -0.310, P = 0.034).
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galantamine treatment was not detected in the current
study. In addition, the long-term AD progression rate
did not correlate with galantamine plasma concentra-
tion. Previous studies that measured the levels of AChE
activity in the CSF instead of the plasma concentration
of ChEIs have reported contradicting results. Our find-
ings are in line with those of Parnetti et al. [17], who
showed no significant relationship between increased
AChE activity and cognitive outcome. A linear associa-
tion between AChE levels and change in MMSE score
was found in one study including primarily donepezil-
treated individuals [10]. Darreh-Shori et al. [9] reported
that patients with high AChE inhibition showed a posi-
tive response, mainly in attention tests after galantamine
therapy. Those 12 individuals with AD had less cogni-
tive impairment and were younger and better educated
than our SATS patients. Another study from that group
including patients treated with donepezil reported a sig-
nificant relationship between AChE inhibition in the
CSF, and stabilised MMSE scores for up to 2 years [22].
These results indicate that the association between
AChE activity or ChEI concentration, and cognitive out-
come is not conclusive. The impact of AChE inhibition
or plasma drug concentration on functional outcome
has not been addressed previously. In this study, no
relationships were observed between higher plasma con-
centrations of galantamine and better functional
outcomes.
The strengths of the 3-year SATS programme are the
prospective, well-structured, semi-annual follow-up
assessments of a large AD cohort of ChEI-treated
patients in clinical practice. A representative group of
patients with mild-to-moderate AD and concomitant ill-
nesses and medications from our Memory Clinic was
included in this study. Conversely, some previous stu-
dies included a small sample size and the participants
were enrolled from randomised clinical trials [9,10]. In
our study, information from two cognitive tests (MMSE
and ADAS-cog) and instrumental ADL ability, as well as
body weight and BMI, were recorded at all evaluations.
The short-term response to ChEI treatment and long-
term rate of cognitive and functional changes were
available measures. To the best of our knowledge, this is
the first study investigating the effects of body weight,
BMI, and sex on the galantamine plasma concentration
in a routine clinical setting.
The patients in the SATS exhibit 100% compliance to
ChEI treatment, and the levels of drug plasma concen-
tration demonstrated a strong relationship to galanta-
mine dose. The high adherence to treatment might
depend on the regular 6-month visits to the Memory
Clinic and the presence of an identified contact nurse
for each patient. The SATS design represents high-qual-
ity individual care, continuity and security for the
patients and their families and has currently evolved
into a clinical follow-up programme that is applied to
all patients with AD in our clinic.
Because the choice and dosage of ChEI for each indi-
vidual patient was left entirely to the physician’s deci-
sion, a common dose-optimising programme for this
study was not applied. However, all dose adjustments
were documented during the study. Plasma extraction
was started while the SATS was ongoing. Therefore, the
galantamine concentration was not measured for all
patients at all time points, as it would be in a phase 1
trial. Our results reflect the outcomes for naturalistic
AD patients in a memory clinic. Galantamine dose
adjustment, changes in other medications and concomi-
tant somatic disorders might have affected the drug
plasma levels and cognitive and ADL abilities of patients
over the course of the study. Another limitation of the
current study is that AChE inhibition was not measured.
However, a study of donepezil showed that AChE inhi-
bition was dose dependent and strongly correlated with
CSF and plasma drug concentration, with the exception
that the concentration of donepezil in the CSF was
approximately ten times lower than was the plasma level
[22].
Table 2 Mean changes in cognitive and functional scores for each quartile of the galantamine plasma concentration
Galantamine plasma
concentration after 2 months





concentration after 6 months












0.42 (-1.17, 2.01) Quartile 1,
< 0.152 μmol/L
1.50 (-0.16, 3.16) -1.90 (-5.51, 1.71) -0.20 (-1.36, 0.96)
Quartile 2,
0.143 to 0.205 μmol/L
0.25 (-1.11, 1.61) Quartile 2,
0.152 to 0.225 μmol/L
-0.36 (-1.33, 0.60) 0.36 (-1.12, 1.84) -2.56 (-4.73, -0.38)
Quartile 3,
0.205 to 0.279 μmol/L
0.67 (-0.58, 1.92) Quartile 3,
0.225 to 0.267 μmol/L
-0.60 (-2.19, 0.99) -0.22 (-4.34, 3.90) -2.89 (-6.36, 0.58)
Quartile 4,
> 0.279 μmol/L
-0.36 (-1.81, 1.09) Quartile 4,
> 0.267 μmol/L
0.50 (-1.74, 2.74) -0.20 (-2.25, 1.85) 0.00 (-1.15, 1.15)
aMean (95% confidence interval). No significant differences in cognitive or functional changes were found among the patients in the different quartiles of the
plasma concentration. ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental
State Examination.
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Future longitudinal studies including larger cohorts
are warranted to investigate further the relationship
between AChE inhibition, plasma or CSF concentration
levels of the ChEI and cognitive and functional outcome.
A dose-optimising schedule would be preferred to
enhance drug efficacy. The mean dose of galantamine
administered during the current study was 14 mg daily,
indicating a potential for dose escalation.
Conclusions
In conclusion, we found high compliance to treatment
among all patients in this naturalistic AD study of galanta-
mine. Drug plasma concentration and dose exhibited a
strong linear relationship. Body weight or BMI, dose of
galantamine, and time from drug intake were critical fac-
tors predicting the plasma concentration in the multivari-
ate models. Obese men exhibited lower galantamine
plasma concentration, indicating a potential for increasing
the drug dose. Galantamine plasma concentration did not
exhibit linear associations with age, cognitive and func-
tional response to ChEI treatment or long-term progres-
sion rate; however, these outcomes might have been
affected by the use of suboptimal doses of galantamine.
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